Jenna M. Marinock
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jenna M. Marinock has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Aamir Ajmeri
Department of Thoracic Medicine and Surgery, Lewis Katz School of Medicine, Temple University, Philadelphia, PA 19140, USA
1 shared publication - Lawrence H. Brent
Temple University Hospital, 3401 N. Broad St., Philadelphia, PA 19140, USA
1 shared publication - Puja Patel
Section of Rheumatology, Temple University Hospital, Philadelphia, PA 19140, USA
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 18 April 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (8) , 4453
A Review of Antisynthetase Syndrome-Associated Interstitial Lung Disease
Our objective in this review article is to present a clinical case of a patient with antisynthetase syndrome (ASyS) and provide an overview of the pathogenesis, classification criteria, antibody profiles, clinical features, and current knowledge of treatment options, focusing on interstitial lung disease (ILD). ASyS is an uncommon autoimmune disease with a heterogenous clinical presentation characterized by the presence of autoantibodies against an aminoacyl-tRNA synthetase and manifested by myositis, fever, inflammatory arthritis, Raynaud’s phenomenon, mechanics hands, and ILD. ASyS-associated ILD (ASyS-ILD) is the most serious complication of ASyS, which may evolve to rapidly progressive ILD; therefore, it often requires thorough clinical and radiologic evaluation including recognition of a specific clinical phenotype associated with the antisynthetase antibodies (ASAbs) to guide therapeutic interventions.
- 18 April 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (8) , 4453
Top Cited PapersOpen AccessA Review of Antisynthetase Syndrome-Associated Interstitial Lung Disease
Our objective in this review article is to present a clinical case of a patient with antisynthetase syndrome (ASyS) and provide an overview of the pathogenesis, classification criteria, antibody profiles, clinical features, and current knowledge of treatment options, focusing on interstitial lung disease (ILD). ASyS is an uncommon autoimmune disease with a heterogenous clinical presentation characterized by the presence of autoantibodies against an aminoacyl-tRNA synthetase and manifested by myositis, fever, inflammatory arthritis, Raynaud’s phenomenon, mechanics hands, and ILD. ASyS-associated ILD (ASyS-ILD) is the most serious complication of ASyS, which may evolve to rapidly progressive ILD; therefore, it often requires thorough clinical and radiologic evaluation including recognition of a specific clinical phenotype associated with the antisynthetase antibodies (ASAbs) to guide therapeutic interventions.